English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Thrombotic disorders are a major cause of death and morbidity worldwide. Thrombolysis like vascular blockage, pulmonary embolism, peripheral occlusive disease, deep vein thrombolysis, stroke and acute myocardial infraction are commonly known as heart attack due to blood clot [1]. Currently, many blood clot-dissolving agents are either approved for clinical use or under clinical examination in patients with acute myocardial infarction, such as staphylokinase, streptokinase, urokinase, tissue plasminogen activator (t-PA) and plasminogen activator recombinant (rscu-PA; recombinant prourokinase) [2]. There is a lot of research available that includes screen and characterization of microorganisms that produce enzymes with high thrombolysis activity since most of the commonly used medicines have complications such as bleeding, allergies, expensive, re-blockage [3]. Hence, thrombolytic therapy needs additional effective thrombolytic drugs, which afford fast improved ef icacy and ibrin speci icity of ibrindissolving agents with minimal side effects like minimal bleeding risk and re-occlusion at low cost [4].

Production and characterization of staphylokinase enzyme from Staphylococcus aureus ASIA4